Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial – a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial

INTRODUCTION: Colistin is a lipopeptide antibiotic administered as an inactive prodrug—colistin methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, dependent on plasma concentrations. The number of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suk, Pavel, Rychlíčková, Jitka, Součková, Lenka, Kubíčková, Vendula, Urbánek, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387630/
https://www.ncbi.nlm.nih.gov/pubmed/37518089
http://dx.doi.org/10.1136/bmjopen-2023-071649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387630/
https://www.ncbi.nlm.nih.gov/pubmed/37518089
http://dx.doi.org/10.1136/bmjopen-2023-071649

Ejemplares similares